Onco. Treatments Pvt Ltd

15/07/2026

Phantom studies and preliminary clinical experience with the Pyrexar BSD 2000 Hyperthermia Machine. For more information please email; [email protected].

Abstract
The BSD 2000 system is an array of microwave antennas operating in the 60-120 MHz range. It is a four-quadrant regional hyperthermia device with phase control permitting the operator to choose the point of constructive interference. A computer preplanning system is provided.

We have compared the computer predictions with measured relative specific absorption rate (SAR) distributions in muscle equivalent phantoms and pig cadaver. The predicted SAR distribution is in qualitative agreement with observation, although differences of approximately 3-5 cm in the location of iso- SAR contours were noted.

The longitudinal dependence of relative of distance cephalad to the central plane of the power distribution was measured, and it was found that a length of 15-20 cm was covered by the 50% iso-SAR. SAR measurements in the spinal canal of a pig cadaver showed that, even at resonance frequency, the measured SAR in the cervical spine was small (0.07 of central axis SAR).

However, the spinal canal SAR as measured in the central plane of an evenly balanced configuration was 0.6 of the peak SAR. Marked reduction of the spinal canal SAR could be obtained with steering techniques and was in good agreement with the computer preplan.

This paper reviews preliminary clinical experience with 17 patients. All but 2 patients were treated with steering techniques to permit partial sparing of normal tissues.

The goal of maintaining central tumour temperature at or above 42 degrees C for at least 30 min was maintained in 41 of 67 sessions (61%) and in at least one session for all but 2 patients. Seventy-seven per cent of monitored tumor points attained at least 42 degrees C in patients for whom thermal mapping was performed. Significant cardiovascular stress developed during hyperthermia in two patients.

There have been five complete responses and seven partial responses in the 17 patients.

15/07/2026

The Pyrexar Hyperthermia system BSD-2000 provides deep regional therapeutic hyperthermia to solid tumors (primarily for cervical cancer). for more information please email; [email protected].

The BSD-2000 provides deep regional therapeutic hyperthermia to solid tumors (primarily for cervical cancer) by applying radiofrequency (RF) energy at the frequency range of 75 to 120 MHz. The BSD-2000 delivers energy to a patient using a power source and an array of multiple antennae that surround the patient’s body. The BSD-2000 was designed to provide an optimized heating zone targeted to the tumor region by utilizing the adjustment of frequency, phase, and amplitude from multiple power sources. The energy can be focused electronically to the tumor region, thus providing dynamic control of the heating delivered to the tumor region.

During a treatment, the cancerous tumor is heated to 40 and 45°C (104 -113 °F). Hyperthermia damages cells in solid tumors, without damaging normal tissues, because higher temperatures selectively damage cells that are hypoxic and have low pH, a condition of tumor cells and not a condition of normal cells. Hyperthermia has been shown to inhibit cellular repair mechanisms, induce heat-shock proteins, denature proteins, induce apoptosis, and inhibit angiogenesis.

The BSD-2000 consists of four major subsystems.

RF power delivery subsystem.
Proprietary, thermistor-based, thermometry subsystem.
Computerized monitoring and control subsystem.
Applicator subsystem that includes an applicator and patient support system.
Various accessories, including a tissue equivalent QA lamp phantom that provides verification of the energy focus, pattern steering, and system operations.

05/05/2026

Gamma Probe for Sentinel Node Biopsy.

Made by Globalsonics, Australia.
For more information Please email; [email protected] or call 0333-2242315.

13/04/2026

Pyrexar Hyperthermia another weapon in the fight against cancer.

10/04/2026

https://youtu.be/pptRLAcXujE?si=F6Rg0HfuyQcv5Smv

Rational for adding thermal oncology to your cancer center

10/04/2026

Pyrexar Bas-2000 Hyperthermia Treatment. No side effects, can treat any size of malignant tumor and metastatic condition.

Paul Turner, CTO of Pyrexar Medical, explains the principals of deep regional hyperthermia using radio frequency

31/03/2026

For more information on Pyrexar BSD Series Hyperthermia Systems, please email; [email protected] or call; 0333-2242315

Improve Head and Neck Cancer Treatment with Hyperthermia

Head and Neck cancer is the sixth most common cancer in worldwide according to World Health Organization and the most common cancer in developing countries. With nearly 664,000 new cases annually. Two-thirds of these occurring in developing countries.

Clinical results like the one below reveal that Radiation treatment are more effective when combined with Hyperthermia. Hyperthermia warms the tumor to temperatures in the "fever range" which makes the cancer cells more sensitive to treatment. Normal healthy cells recover while cancer cells die.

Clinical Evidence
Tumor Entity:
Advanced Head and Neck Tumors with Lymph Node Metastasis

Treatment Modality:
In three trials patients with head and neck tumors were randomized to radio(chemo)therapy with or without hyperthermia. Radiotherapy was applied with 2 Gy fractions up to a total dose of 66-70 Gy. Chemotherapy was only applied in the study by Hua et al., to patients with T3-T4 tumors only. Hyperthermia was given once or twice weekly Valdagni, Trento Italy study used BSD-1000.

Clinical Results:
All three studies showed a significant improvement in complete response rate, and higher local tumor control and overall survival rates, or a longer median survival, when radio(chemo)therapy was combined with hyperthermia.

RT alone RT plus Hyperthermia
CR LC OS CR LC OS
Valdagni 41% 5-y 24% 5-y 0% 83% 5-y 69% 5-y 53%
Hua 81% 5-y 79% 5-y 70% 95% 5-y 91% 5-y 78%
Huilgol 42% not reported median 0.40 y 79% not reported median 0.66 y


41 pts, 44 nodes. Radiotherapy 64-70 GY, 5 fractions/week of 2-2.5 Gy
Complete Remission Rate without Hyperthermia: 41 %
Complete Remission Rate with Hyperthermia: 83 %
5yr nodal control RT - 24%; RT+HT - 69%
5yr overall survival RT - 0% RT+HT - 53%
No enhancement of acute or late toxicity
Endorsements:
The combination of Radiotherapy and Hyperthermia is the treatment of choice for Head & Neck Cancer (Level I Evidence) recommended by

DEGRO German Society of Radiation Oncology
DKG Deutsche Krebsgesellschaft, Germany
Dutch Society for Radiation Oncology, The Netherlands
Dutch Cancer Society, The Netherlands
ESHO European Society of Hyperhermic Oncology
Hyperthermia and Chemotherapy:
When hyperthermia is combined with chemotherapy, general treatment guidelines of the ESHO European Society of Hyperthermic Oncology recommend:

Target volume for hyperthermia: The target volume for hyperthermia is the gross tumor volume.
Sequence of treatment modalities: Hyperthermia is given simultaneously with chemotherapy during cytostasis.
Duration of hyperthermia treatment: Superficial hyperthermia total 60 minutes, deep hyperthermia total 90 minutes (including 30 minutes heating-up time) ) at temperatures of 40 to 44 °C in the whole target volume

31/03/2026

For more information on Pyrexar BSD Hyperthermia Systems please email; [email protected] or Call; 0333-2242315.

Improve Esophageal Cancer Treatment Results with Hyperthermia

Esophageal (Oesophageal) cancer is the eighth most common cancer worldwide according to the World Cancer Research Fund International. With nearly 456,000 new cases diagnosed in 2012. About 75% of those cases are diagnosed in Asia.

Level 1 Clinical results like the one below reveal that both Chemotherapy and Radiation treatment are more effective when combined with Hyperthermia. Hyperthermia warms the tumor to temperatures in the "fever range" which makes the cancer cells more sensitive to treatment. Normal healthy cells recover while cancer cells die.

Clinical Evidence
Tumor Entity:
Primary thoracic esophageal cancer stage III and IV

Treatment Modality:
Three randomized studies were performed in esophageal cancer, comparing radio and/or chemotherapy with or without intraluminal hyperthermia. Kitamura et al. compared preoperative radiochemotherapy with or without hyperthermia. Wang et al. compared 60 Gy alone to 40 Gy plus hyperthermia. Sugimachi et al. compared preoperative chemotherapy with or without hyperthermia. Third party hyperthermia devices used.

esophagus ht table

Clinical Results:
Kitamura et al. found a significantly higher pCR in the plus hyperthermia treatment arm: 25% vs 6%.
Wang et al. found a significantly better 3-y overall survival with hyperthermia: 42 vs 24%.

Sugimachi et al. found that the local effects tended to be better in the plus hyperthermia group: improvement of dysphagia 70% vs 40%; radiographic improvement 50% vs 25%, and histopathological evidence of treatment effect 41% vs 19%.
Duration of hyperthermia treatment
Intraluminal hyperthermia total 30 minutes

References:
Kitamura et al. Prospective Randomised Study of Hyperthermia Combined with Chemoradiotherapy for Esophageal Carcinoma. J Surgical Oncology. 1995; 60:55-58.
Wang et al. Intracavitary microwave hyperthermia combined with external irradiation in the treatment of esophageal cancer. Chung Hua Chung Liu Tsa Chih 1996;18:51-54.
Sugimachi et al. Chemotherapy combined with or without hyperthermia for patients with oesophageal carcinoma: a prospective trial. Int J Hyperthermia 1994;10:485-4